ACTILYSE 2 mg, poudre pour solution injectable et perfusion

( ARTG ) Myocardial Infarction: ACTILYSE is indicated for intravenous use in adults for the lysis of suspected occlusive coronary artery thrombi associated with evolving transmural myocardial infarction.​​​‍​​‍​​​​‍​​‍‍ Treatment should be initiated as soon as possible after the onset of symptoms. The treatment can be initiated within 12 hours of symptom onset.,Pulmonary Embolism:ACTILYSE is also indicated in patients with acute massive pulmonary embolism in whom thrombolytic therapy is considered appropriate.,Acute Ischaemic Stroke:ACTILYSE is indicated for thrombolytic treatment of acute ischaemic stroke. Treatment must be started as early as possible within 4.5 hours after onset of stroke symptoms and after exclusion of intracranial haemorrhage by appropriate imaging techniques (e.g. cranial computerised tomography or other diagnostic imaging method sensitive for the presence of haemorrhage). The treatment effect is time-dependent; therefore earlier treatment increases the probability of a favourable outcome.